Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?

Near term, the stock is trading more like an event-driven platform story than a fundamentals story, so the key question is not approval itself but whether the next 2-3 quarters can show durable mix shift away from a shrinking legacy revenue base. A clean regulatory win on the flu candidate may lift sentiment, but the first derivative is likely modest unless management can pair it with evidence of pricing power, payer acceptance, and lower cash burn translating into operating leverage.

The bigger second-order effect is competitive: a successful combination respiratory vaccine would force rivals in flu and COVID-adjacent immunization to defend share with discounts, bundling, or broader distribution agreements. That favors scale players with manufacturing and commercial reach, but it also raises the bar for standalone vaccine economics; investors should watch whether the market starts valuing MRNA on gross profit durability rather than headline revenue growth.

Contrarian view: consensus may be underestimating how binary the pipeline still is. One approval does not solve the prior pattern of commercial underdelivery, and biotech reratings often fade once the binary event passes unless launch metrics change. The key falsifier is not price action, but evidence that the new products can consistently add incremental revenue without offsetting margin pressure; if the flu decision slips or launch adoption disappoints into the next two earnings prints, the current rerating likely unwinds.